J. Sieper and D. Poddubnyy, Axial spondyloarthritis, Lancet, vol.390, pp.73-84, 2017.

N. Garg, F. Van-den-bosch, and A. Deodhar, The concept of spondyloarthritis: where are we now?, Best Pract Res Clin Rheumatol, vol.28, issue.5, pp.663-672, 2014.

J. J. De-winter, L. J. Van-mens, D. Van-der-heijde, R. Landewe, and D. L. Baeten, Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis, Arthritis Res Ther, vol.18, p.196, 2016.

N. Zeboulon, M. Dougados, and L. Gossec, Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review, Ann Rheum Dis, vol.67, issue.7, pp.955-959, 2008.

G. J. Jaffe, A. D. Dick, and A. P. Brézin, Adalimumab in Patients with Active Noninfectious Uveitis, N Engl J Med, vol.375, issue.10, pp.932-943, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02741384

Q. D. Nguyen, P. T. Merrill, and G. J. Jaffe, Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial, Lancet, vol.388, issue.16, pp.31339-31342, 2016.

S. Guignard, L. Gossec, and C. Salliot, Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study, Ann Rheum Dis, vol.65, issue.12, pp.1631-1634, 2006.

J. Braun, X. Baraliakos, J. Listing, and J. Sieper, Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept, Arthritis Rheum, vol.52, issue.8, pp.2447-2451, 2005.

E. Lie, U. Lindström, and T. Zverkova-sandström, Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register, Ann Rheum Dis, vol.76, issue.9, pp.1515-1521, 2017.

J. C. Van-denderen, I. M. Visman, M. T. Nurmohamed, M. Suttorp-schulten, and I. E. Van-der-horst-bruinsma, Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis, J Rheumatol, vol.41, issue.9, pp.1843-1848, 2014.

M. Rudwaleit, J. T. Rosenbaum, and R. Landewé, Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis, Arthritis Care Res (Hoboken), vol.68, issue.6, pp.838-844, 2016.

S. Faez, A. Lobo, L. Sobrin, and G. N. Papaliodis, Treatment of seronegative spondyloarthropathyassociated uveitis with golimumab: retrospective case series, Clin Experiment Ophthalmol, vol.42, issue.4, pp.392-395, 2014.

R. E. Van-bentum, S. C. Heslinga, and M. T. Nurmohamed, Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab -The GO-EASY Study, J Rheumatol, vol.46, issue.2, pp.153-159, 2019.

D. Wu, Y. Guo, and N. Xu, Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis, BMC Musculoskelet Disord, vol.16, issue.1, 2015.

S. M. Sharma and D. Jackson, Uveitis and spondyloarthropathies, Best Pract Res Clin Rheumatol, vol.31, issue.6, pp.846-862, 2017.

A. D. Dick, I. Tugal-tutkun, and S. Foster, Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology, vol.120, issue.4, pp.777-787, 2013.

A. A. Deodhar, C. Miceli-richard, and X. Baraliakos, Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies, ACR Open Rheumatol, vol.2, issue.5, pp.294-299, 2020.

M. Rudwaleit, D. Van-der-heijde, and R. Landewé, The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection, Ann Rheum Dis, vol.68, issue.6, pp.777-783, 2009.

, Meta-Analysis Manual V3.pdf. Accessed, 2020.

G. Rücker, G. Schwarzer, U. Krahn, and J. König, Network Meta-Analysis using Frequentist Methods, 2015.

R. D. Inman, W. P. Maksymowych, . Candle-study, and . Group, A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis, J Rheumatol, vol.37, issue.6, pp.1203-1210, 2010.

A. Deodhar, L. S. Gensler, and J. Kay, A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis, Arthritis & Rheumatology, vol.71, issue.7, pp.1101-1111, 2019.

J. Sieper, D. Van-der-heijde, and M. Dougados, A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis, Arthritis & Rheumatology, vol.67, issue.10, pp.2702-2712, 2015.

N. Barkham, H. I. Keen, and L. C. Coates, Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis, Arthritis Rheum, vol.60, issue.4, pp.946-954, 2009.

F. Huang, J. Gu, and P. Zhu, Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial, Ann Rheum Dis, vol.73, issue.3, pp.587-594, 2014.

D. Van-der-heijde, A. Kivitz, and M. H. Schiff, Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, vol.54, issue.7, pp.2136-2146, 2006.

J. Sieper, D. Van-der-heijde, and M. Dougados, Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1), Ann Rheum Dis, vol.72, issue.6, pp.815-822, 2013.

R. D. Inman, J. C. Davis, and . Heijde-d-van-der, Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial, Arthritis Rheum, vol.58, issue.11, pp.3402-3412, 2008.

D. Van-der-heijde, B. Dijkmans, and P. Geusens, Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT), Arthritis Rheum, vol.52, issue.2, pp.582-591, 2005.

J. Sieper, J. Lenaerts, and J. Wollenhaupt, Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the doubleblind, placebo-controlled INFAST study, Part 1, Ann Rheum Dis, vol.73, issue.1, pp.101-107, 2014.

R. Landewé, J. Braun, and A. Deodhar, Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study, Ann Rheum Dis, vol.73, issue.1, pp.39-47, 2014.

H. Marzo-ortega, D. Mcgonagle, and S. Jarrett, Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study, Ann Rheum Dis, vol.64, issue.11, pp.1568-1575, 2005.

A. Deodhar, J. D. Reveille, and D. D. Harrison, Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study, J Rheumatol, vol.45, issue.3, pp.341-348, 2018.

C. Bao, F. Huang, and M. A. Khan, Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial, Rheumatology (Oxford), vol.53, issue.9, pp.1654-1663, 2014.

J. Braun, J. Brandt, and J. Listing, Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial, Lancet, vol.359, issue.9313, pp.1187-1193, 2002.

A. R. Giardina, A. Ferrante, and F. Ciccia, A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis, Rheumatol Int, vol.30, issue.11, pp.1437-1440, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00562259

D. Van-der-heijde, C. Wei, J. Dougados, and M. , Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebocontrolled trial, Lancet, vol.392, issue.18, pp.31946-31955, 2018.

N. Barkham, L. C. Coates, and H. Keen, Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis, Ann Rheum Dis, vol.69, issue.11, pp.1926-1928, 2010.

M. Dougados, J. Braun, and S. Szanto, Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE), Ann Rheum Dis, vol.70, issue.5, pp.799-804, 2011.

D. Van-der-heijde, D. Silva, J. C. Dougados, and M. , Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis, Ann Rheum Dis, vol.65, issue.12, pp.1572-1577, 2006.

M. Dougados, E. Wood, and B. Combe, Evaluation of the nonsteroidal anti-inflammatory drugsparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study, Arthritis Res Ther, vol.16, issue.6, p.481, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01112377

A. Calin, B. Dijkmans, .. C. Emery, and P. , Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis, Ann Rheum Dis, vol.63, issue.12, pp.1594-1600, 2004.

J. C. Davis, D. Van-der-heijde, and J. Braun, Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial, Arthritis Rheum, vol.48, issue.11, pp.3230-3236, 2003.

J. Brandt, A. Khariouzov, and J. Listing, Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis, Arthritis Rheum, vol.48, issue.6, pp.1667-1675, 2003.

M. Dougados, D. Van-der-heijde, and J. Sieper, Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatology, vol.66, issue.8, pp.2091-2102, 2014.

J. D. Gorman, K. E. Sack, and J. C. Davis, Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha, N Engl J Med, vol.346, issue.18, pp.1349-1356, 2002.

A. Deodhar, D. Poddubnyy, and C. Pacheco-tena, Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors, Arthritis & Rheumatology, vol.71, issue.4, pp.599-611, 2019.

A. J. Kivitz, U. Wagner, and E. Dokoupilova, Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study, Rheumatol Ther, vol.5, issue.2, pp.447-462, 2018.

K. Pavelka, A. Kivitz, and E. Dokoupilova, Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3, Arthritis Res Ther, vol.19, issue.1, p.285, 2017.

D. Baeten, J. Sieper, and J. Braun, Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis, N Engl J Med, vol.373, issue.26, pp.2534-2548, 2015.

D. Baeten, X. Baraliakos, and J. Braun, Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial, Lancet, vol.382, issue.9906, pp.1705-1713, 2013.

A. Deodhar, R. Blanco, and E. Dokoupilová, Secukinumab improves signs and symptoms of nonradiographic axial spondyloarthritis: primary results of a randomized controlled phase III study, Arthritis & Rheumatology, 2020.

A. Deodhar, D. Van-der-heijde, and L. S. Gensler, Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial, Lancet, vol.395, pp.53-64, 2020.

C. S. Foster, F. Tufail, and N. K. Waheed, Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate, Arch Ophthalmol, vol.121, issue.4, pp.437-440, 2003.

J. A. Smith, D. Thompson, and S. M. Whitcup, A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis, Arthritis Rheum, vol.53, issue.1, pp.18-23, 2005.

D. Wendling, A. Joshi, P. Reilly, Y. J. Jalundhwala, M. Mittal et al., Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database, Curr Med Res Opin, vol.30, issue.12, pp.2515-2521, 2014.

R. Landewé, , 2013.

, GOL IV 2 mg/kg at wk 0, 4, 12 and then / 8 wk Placebo 28

J. Sieper, , 2015.

, IFX 5 mg/kg at wk 0, vol.2, p.24

, IFX 5 mg / kg at wk 0, vol.2, p.12

R. Inman, Infliximab 39 Placebo 37 IFX 3 mg / kg at wk 0, vol.2, p.6, 2010.

, IFX 5 mg / kg at wk 0, 2, 6, 14 and 22 Placebo 30

J. Sieper, Infliximab 105 Placebo 52 IFX 5 mg / kg at wk 0, 2, 6, 12, vol.18, p.28, 2012.

J. Braun, Infliximab 34 Placebo 35 IFX 5 mg / kg at wk 0, vol.35, p.6, 2002.

J. D. , , 2002.

, SCK 150mg at wk 0,1,2,3 and then /4wk SCK 150mg at wk 0 and then /4wk Placebo 52

D. Baeten, Secukinumab 24 Placebo 6 SCK IV 10 mg/kg /3wk Placebo 28, vol.51, 2013.

D. Baeten, Secukinumab 394 Placebo 196 SCK IV 10 mg/kg /2wk 3x then 150 mg/4wk SCK IV 10 mg/kg /2wk 3x then 75 mg/4wk SCK 150 mg at wk 0,1,2,3 and then /4wk SCK 75 mg, vol.50, 2015.

, Risque de biais dans les ECR inclus, vol.2, p.33

, Annexe 3: Funnel plot